The company's software automatically predicts the probability of clinically significant disease onset, progression, and good or poor therapy response. The company's goal is to develop software to estimate the risk of cardiovascular disease or poor outcome after surgical treatment, the risk of malignant breast lesions, and the risk of Alzheimer's disease.

The initial seed funding round was led by Progress Tech Transfer, with the strategic advisor MITO Technology.

DeepTrace Technologies' AI tools have been adopted by Italian research institutes and DeepTrace wants to expand its customer base not only in Europe but also in North America and Asia.